Evaxion A (EVAX) Non-Current Deferred Tax Liability (2022 - 2025)
Evaxion A posted quarterly Non-Current Deferred Tax Liability of $156000.0 for Q4 2025, up 19.08% year-on-year from $131000.0 in Q4 2024, and up 19.08% on a QoQ basis from $131000.0 in Q4 2024.
Evaxion A (EVAX) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $156000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 19.08% year-over-year to $156000.0; the trailing twelve-month figure through Dec 2025 stood at $156000.0 (up 19.08% YoY), and the FY2025 full-year result was $156000.0, up 19.08% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $156000.0, up from $131000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $214000.0 in Q4 2022 and bottomed at $126000.0 in Q4 2023.
- The 4-year median for Non-Current Deferred Tax Liability is $143500.0 (2024), against an average of $156750.0.
- The widest annual swing landed in 2023, when Non-Current Deferred Tax Liability plunged 41.12%; it then climbed 19.08% in 2025.
- A 4-year view of Non-Current Deferred Tax Liability shows it stood at $214000.0 in 2022, then sank by 41.12% to $126000.0 in 2023, then climbed by 3.97% to $131000.0 in 2024, then gained by 19.08% to $156000.0 in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $156000.0 (Q4 2025), $131000.0 (Q4 2024), and $126000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 126,000.00 |
| Dec 31, 2023 | 126,000.00 |
| Dec 31, 2022 | 214,000.00 |
| Dec 31, 2022 | 214,000.00 |